Jiangsu Aosaikang IPO Launch Halted As China Changes Rules
This article was originally published in PharmAsia News
Executive Summary
China regulators reportedly halted Jiangsu Aosaikang Pharmaceutical's planned initial public offering on the local stock market because the price of the shares offered was too high.